While MR-356 prevented the increase in aortic blood pressure induced by Ang-II in the 4 weeks experimental model (when the treatment was initiated simultaneously with the Ang-II-infusion), Kanashiro-Takeuchi et al. did not detect a reduction in arterial hypertension in mice with an established cardiometabolic HFpEF phenotype [20]. The gene discussed is AGT; the disease is Hypertension.